Print    

Home Page / News and Events / Press Releases / Press Release Details ...


May 28, 2009

BioTrove Launches RapidFire 300 for in vitro ADME Discovery

Advanced High-Throughput Mass Spectrometry Platform for High-Quality in vitro ADME Analysis Unveiled at ASMS Conference, May 31 - June 4

Two Oral Presentations and Four Posters on RapidFire Will be Presented. Scientists from BI, J&J and Merck to Speak at RapidFire 300 Launch Event

Woburn, MA, May 28, 2009 – BioTrove, Inc. announced the launch of its RapidFire® 300 system for high-throughput screening of in vitro ADME assays.  Producing label-free data at six to eight seconds per sample, drug discovery researchers can now use the high-throughput, mass spectrometry based method to analyze in vitro ADME assays in a fraction of the time required for conventional HPLC mass spectrometry techniques. The RapidFire 300 expands the in vitro ADME applications of the platform beyond drug-drug interaction (DDI) screening.  DDI was first launched two years ago on the RapidFire 200 system and is used by numerous pharmaceutical and biotechnology companies to provide high quality DDI data at record throughput.  This latest addition to the RapidFire screening tool kit will be introduced at the American Society for Mass Spectrometry’s (ASMS) 57th Annual Conference in Philadelphia, Pennsylvania, May 31-June 4, 2009.

As the newest addition to the RapidFire instrumentation portfolio, the RapidFire 300 system enables researchers to perform a wide range of in vitro ADME assays with 24-hour, unattended operation.  The RapidFire-MS system streamlines drug discovery workflow, significantly decreasing the processing time compared to conventional MS-based technologies and helps to eliminate bottlenecks in drug discovery while providing accurate results for data-driven decision making. RapidFire 300 can fully integrate with any manufacturer’s triple quadrupole mass spectrometer and provide data compatible with customers’ existing laboratory information management systems.

“ADME data is critical in all phases of a fully integrated drug development program but data in the lead discovery stage was previously limited by time and labor intensive screening platforms,” said Can “Jon” Özbal, Ph.D., Vice Chief Operating Officer, BIOCIUS.  “RapidFire 300 was developed to meet investigators’ demand for high quality in vitro ADME data with a short turnaround time.”

The RapidFire 300 system can be used for a variety of in vitro ADME applications, including:

• CYP Inhibition
• Metabolic Stability
• P-Glycoprotein Inhibition
• Plasma Protein Binding
• Permeability Assays - Caco, PAMPA
• CYP Induction

Scientists from Boehringer Ingelheim, Merck, and Johnson & Johnson will speak about advancing drug discovery and their experience with the RapidFire system. 

BIOCIUS researchers and customers will also present talks and posters at the conference on the RapidFire system as follows:

Oral Session – Chromatography-Mass Spectrometry Approaches to Increase Throughput in Discovery PK Assays, Ballroom B (10:10 a.m.)
A Novel and Integrated Platform for Fully Automated High-Throughput LCMSMS Analysis of in vitro ADME Samples; A. Luippold, T. Arnhold, W. Joerg, K. Klinder, K. Schumacher; Boehringer Ingelheim Pharma GmbH & Co KG.

Oral Session – Tandem MS of Whole Proteins and Protein Complexes, Room 201 (3:10 p.m.)
High Throughput Quantitative Screening Measuring Intact Proteins by a Novel Rapid Mass Spectrometric Approach; K. Alving, G. Asmussen, T. Gladysheva, J. Lillie, A. Cohen, B. Wang; Genzyme Corporation.

Poster Sessions – Drug Metabolism: High Throughput, Exhibit Hall AB (10:30 a.m. - 2:30 p.m.)
P 437:  Application of the (BIOCIUS) RapidFire® Ultra-fast Online SPE-MS/MS System for Compound-specific Analysis of in-vitro ADME Samples; A. Paiva, A. Wagner, X. Cai, Y. Li, J. Kolb, J. Herbst, C. Conway, H. Weller, W. Shou; Bristol-Myers Squibb. 
P 438:  Evaluation of accurate mass TOF-MS for use in high throughput CYP450 inhibition screening; W. LaMarr, M. Romm, N. Parikh, L. Frick, C. Özbal; BIOCIUS

Poster Sessions – High Throughput Analysis/Robotics, Exhibit Hall AB (10:30 a.m. - 2:30 p.m.)
P 669:  Label Free High-Throughput Whole Protein Kinase Screening Assay; M. Romm, N. Parikh, T. Stanley, J. Williams, W. Lamarr, C. Özbal; BIOCIUS, GlaxoSmithKline.
P 677: Discovery of Novel Inhibitors of Serine Palmitoyltransferase (SPT) by Mass Spectrometry-Based High-Throughput Screening (HTS); P. Meyn, P. Maresca, W. Lamarr, P. Rye, M. Brooks, A. Babbs, M. Procter, D. Pan, C. Özbal, A. Garton; OSI Pharmaceuticals, BIOCIUS Life Sciences, Prosidion Limited.

About BIOCIUS Life Sciences
BIOCIUS Life Sciences provides researchers faster answers to their lead discovery and in vitro ADME analyses through its RapidFire instrument and contract research services. RapidFire® enables the acceleration of drug discovery and pipeline decisions.  With 13 of the top 15 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BIOCIUS’s products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFire® Mass Spectrometry (RF-MS) feeds samples directly to the mass spectrometer at six to eight seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RF-MS is routinely used in many applications including the high-throughput screening of previously intractable drug targets and ADME assays.

BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,